Ciloa is dedicated to the production of fully native membrane proteins on exosomes. Based in Montpellier, France, the company was created in 2011 by Robert MAMOUN and Bernadette TRENTIN. The company is a spin-off of the CNRS and the University of Montpellier.

It has exclusive proprietary technology for developing recombinant exosomes in therapeutic and preventive applications.

Ciloa exosomes offer a disruptive way to develop a new generation of therapeutic and preventive vaccines, monoclonal antibodies, immunotherapies, and therapeutic vectors carrying drug cargo. Its unique technology allows to drug undruggable targets.

Based on 2 international families of patents under worldwide exclusive license, its technology has full freedom to operate.



Ciloa is dedicated to the development of new high-potential therapies through its bio-drug development technology using exosomes.


Ciloa has already developed a pioneering technology for more than 15 years.


Ciloa's management team is dedicated to science and innovation, and has the skills to lead high potential therapies development.


Ciloa’s business model includs partnerships, at the scientific and academic level, as well as at the commercial level in the development of drug candidates.